2009
DOI: 10.1007/s11094-009-0340-x
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis and pharmacological activity of 3-(2,2,2-trichloro-1-hydroxyethyl)imidazo [1, 2-a]benzimidazole dihydrochlorides

Abstract: A series of 3-(2,2,2-trichloro-1-hydroxyethyl)imidazo[1, 2-a]benzimidazole dihydrochlorides have been synthesized and their pharmacological properties have been studied. It is established that the synthesized compounds exhibit weak antioxidant activity. In addition, they possess platelet and erythrocyte antiaggregant properties, show pronounced spasmolytic action, and have low toxicity. Some of them also exhibit antiradiomimetic, hypotensive, and antiarrhythmic properties.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
9
0
1

Year Published

2010
2010
2020
2020

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 15 publications
(10 citation statements)
references
References 8 publications
0
9
0
1
Order By: Relevance
“…Amides of 2,3-dihydroimidazo-and 2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazolyl-acetic acids showed moderate AO activity compared to dibunol [18]. It was revealed that 2-methoxy-phenyl-and 2-oxyphenyl-substituted 1-dialkylaminoalkyl-IMBI [8], N-acylmethyl derivatives of 9H-2,3-dihydro-IMBI and 10H-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [9], most of 3-(2,2,2-trichloro-1-hydroxyethyl)-IMBI [12] и 3-acetyl-2-R-9-dialkylaminoethyl-IMBI [13], 1-dialkyl(alkyl)aminoethyl-2,3-dihydro-IMBI [14], and 3-(n,n-disubstituted)acetamide-1-r-2-aminobenzimidazolium [17] showed the weak antioxidant activity compared to the reference drug. Among 10-alkylaminoethyl-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [16] and phenyl-and alkylthiocarbamides of 2,9-disubstituted IMBI [19], antioxidant action has not been found.…”
Section: The Resultsmentioning
confidence: 99%
“…Amides of 2,3-dihydroimidazo-and 2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazolyl-acetic acids showed moderate AO activity compared to dibunol [18]. It was revealed that 2-methoxy-phenyl-and 2-oxyphenyl-substituted 1-dialkylaminoalkyl-IMBI [8], N-acylmethyl derivatives of 9H-2,3-dihydro-IMBI and 10H-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [9], most of 3-(2,2,2-trichloro-1-hydroxyethyl)-IMBI [12] и 3-acetyl-2-R-9-dialkylaminoethyl-IMBI [13], 1-dialkyl(alkyl)aminoethyl-2,3-dihydro-IMBI [14], and 3-(n,n-disubstituted)acetamide-1-r-2-aminobenzimidazolium [17] showed the weak antioxidant activity compared to the reference drug. Among 10-alkylaminoethyl-2,3,4,10-tetrahydropyrimido[1,2-a]benzimidazoles [16] and phenyl-and alkylthiocarbamides of 2,9-disubstituted IMBI [19], antioxidant action has not been found.…”
Section: The Resultsmentioning
confidence: 99%
“…The object of this study is to investigate the inhibition properties of a group of some newly synthesised diazoles that acts as corrosion inhibitor for steel in acidic media [27][28][29][30] and easy to produce with purities greater than 99%. All of the compounds investigated are reported here for the first time.…”
Section: Introductionmentioning
confidence: 99%
“…It is known that many diseases reduce its antithrombotic potential. In addition, side effects of the known antiplatelet agent acetylsalicylic acid are associated with prostacyclin production suppression by the vascular wall [12].Previous studies have shown the ability of substituted heterocyclic nitrogen-containing compounds to inhibit platelet aggregation [1,7,9]. Among the new indole derivatives, compound Sbt-828 exhibited high antithrombogenic activity in vitro and in vivo [8], so it seemed interesting to find out whether the antiplatelet action of this compound is related to the influence on the prostacyclin-thromboxane balance.…”
mentioning
confidence: 99%
“…Previous studies have shown the ability of substituted heterocyclic nitrogen-containing compounds to inhibit platelet aggregation [1,7,9]. Among the new indole derivatives, compound Sbt-828 exhibited high antithrombogenic activity in vitro and in vivo [8], so it seemed interesting to find out whether the antiplatelet action of this compound is related to the influence on the prostacyclin-thromboxane balance.…”
mentioning
confidence: 99%